IN2012DE00661A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00661A
IN2012DE00661A IN661DE2012A IN2012DE00661A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A IN 661DE2012 A IN661DE2012 A IN 661DE2012A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A
Authority
IN
India
Prior art keywords
substituted
hetero
aminoquinoline
aryl
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Singh Rawat Diwan
Manohar Sunny
Chinna Rajesh Ummadisetty
Original Assignee
Univ Delhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delhi filed Critical Univ Delhi
Priority to PCT/US2013/028329 priority Critical patent/WO2013134047A2/en
Priority to EP13758678.0A priority patent/EP2822936B1/en
Priority to PT137586780T priority patent/PT2822936T/pt
Priority to EP21194376.6A priority patent/EP3971178A1/en
Priority to IN661DE2012 priority patent/IN2012DE00661A/en
Priority to US14/382,727 priority patent/US9567316B2/en
Priority to ES13758678T priority patent/ES2899730T3/es
Publication of IN2012DE00661A publication Critical patent/IN2012DE00661A/en
Priority to US15/404,964 priority patent/US11026943B2/en
Priority to US17/240,886 priority patent/US20220008418A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN661DE2012 2012-03-07 2013-02-28 IN2012DE00661A (enExample)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/US2013/028329 WO2013134047A2 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
EP13758678.0A EP2822936B1 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
PT137586780T PT2822936T (pt) 2012-03-07 2013-02-28 Derivados da aminoquinolina e suas utilizações
EP21194376.6A EP3971178A1 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
IN661DE2012 IN2012DE00661A (enExample) 2012-03-07 2013-02-28
US14/382,727 US9567316B2 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
ES13758678T ES2899730T3 (es) 2012-03-07 2013-02-28 Derivados de la aminoquinolina y sus usos
US15/404,964 US11026943B2 (en) 2012-03-07 2017-01-12 Aminoquinoline derivatives and uses thereof
US17/240,886 US20220008418A1 (en) 2012-03-07 2021-04-26 Aminoquinoline Derivatives and Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN661DE2012 IN2012DE00661A (enExample) 2012-03-07 2013-02-28

Publications (1)

Publication Number Publication Date
IN2012DE00661A true IN2012DE00661A (enExample) 2015-08-21

Family

ID=49117483

Family Applications (1)

Application Number Title Priority Date Filing Date
IN661DE2012 IN2012DE00661A (enExample) 2012-03-07 2013-02-28

Country Status (6)

Country Link
US (3) US9567316B2 (enExample)
EP (2) EP3971178A1 (enExample)
ES (1) ES2899730T3 (enExample)
IN (1) IN2012DE00661A (enExample)
PT (1) PT2822936T (enExample)
WO (1) WO2013134047A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188077A1 (en) * 2014-06-06 2015-12-10 Board Of Trustees Of Michigan State University Nurr1 as a genetic target for treating levodopa-induced dyskinesias in parkinson's disease
CN104070943B (zh) * 2014-07-23 2017-10-17 万通智控科技股份有限公司 一种自编程轮胎压力监测装置及实现方法
WO2016111957A1 (en) * 2015-01-06 2016-07-14 Albert Einstein College Of Medicine, Inc. Chloroquinoline triazole compounds, composition and uses
CN107249588A (zh) 2015-02-16 2017-10-13 浦项工科大学校产学协力团 包含阿莫地喹作为有效成分的代谢性疾病的预防、改善或治疗用组合物
US10329258B2 (en) 2015-04-30 2019-06-25 University Of Washington CGAS in systemic lupus erythematosus (SLE)
JP2018517743A (ja) 2015-06-15 2018-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 多系統萎縮症を治療するための自家間葉系幹細胞の使用
CN105301126B (zh) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 一种托匹司他有关物质的分析方法
JP6861795B2 (ja) 2016-08-12 2021-04-21 ノブメタファーマ カンパニー リミテッド アモジアキンおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
EP3810126A4 (en) * 2018-06-21 2022-04-27 Board of Regents of the Nevada System of Higher Education, on Behalf of the University of Nevada, Reno DISEASE MODIFYING METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES USING NOOTROPIC AGENTS
CN109620971A (zh) * 2018-12-14 2019-04-16 昆明医科大学第附属医院 一种筛选防治帕金森病药物的方法
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
US11248001B2 (en) * 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
PH12022550370A1 (en) * 2019-08-22 2023-03-06 Biohaven Therapeutics Ltd Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
WO2021087077A1 (en) * 2019-10-29 2021-05-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of autophagy and histone deactylases and uses thereof
CN115843247A (zh) * 2020-07-07 2023-03-24 麦克莱恩医院公司 用于治疗神经退行性疾病的化合物和方法
US20240148722A1 (en) * 2021-02-20 2024-05-09 Biohaven Therapeutics Ltd. Small molecules that bind to tdp-43 for the treatment of als and related disorders
WO2023159062A2 (en) * 2022-02-15 2023-08-24 University Of Central Florida Research Foundation, Inc. Anabolic drugs stimulating type ii collagen production from chondrocytes or their progenitors
WO2024049718A2 (en) * 2022-08-31 2024-03-07 Immunocure Inc. Quinoline piperazine derivatives, pharmaceutical composition and uses thereof
US20240182423A1 (en) * 2022-10-28 2024-06-06 United States Government As Represented By The Department Of Veterans Affairs 4-aminoquinolines for treatment of multidrug resistant malaria
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL278921A (enExample) * 1961-05-26
BE626239A (enExample) 1961-12-29 1900-01-01
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4487761A (en) 1982-04-05 1984-12-11 Merck & Co., Inc. Dopamine β-hydroxylase inhibitors
US4992459A (en) 1983-04-12 1991-02-12 Smithkline Beecham Corporation Dopamine-β-hydroxylase inhibitors
US4906668A (en) 1984-08-23 1990-03-06 Georgia Tech Research Corporation Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions
US4634711A (en) 1985-08-02 1987-01-06 Smithkline Beckman Corporation Pyridylalkyl imidazole-2-thiols
US4719223A (en) 1985-10-31 1988-01-12 Smithkline Beckman Corporation Imidazolethiol dopamine-beta-hydroxylase inhibitors
US4743613A (en) 1986-04-08 1988-05-10 Smithkline Beckman Corporation Ester prodrugs of dopamine-β-hydroxylase, inhibitors, composition containing them, and method of using them to inhibit dopamine-β-hydroxylase activity
US5189052A (en) 1986-05-06 1993-02-23 Merrell Dow Pharmaceuticals Inc. Thione dopamine beta hydroxylase inhibitors
US4810800A (en) 1986-05-06 1989-03-07 Merrell Dow Pharmaceuticals Inc. Novel imidazole dopamine beta hydroxylase inhibitors
US4761415A (en) 1986-08-28 1988-08-02 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4749717A (en) 1987-01-08 1988-06-07 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
US4859779A (en) 1987-03-24 1989-08-22 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4762850A (en) 1987-03-24 1988-08-09 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
US4835154A (en) 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US4798843A (en) 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
US4839371A (en) 1987-09-17 1989-06-13 Smithkline Beckman Corporation 3-aralkyl-2-mercaptoyridines as dopamine-β-hydroxylase inhibitors
US4935438A (en) 1987-12-29 1990-06-19 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4882348A (en) 1987-12-29 1989-11-21 Smithkline Beckman Corporation 2-(aminoalkylthio)imidazoles as dopamine-β-hydroxylase inhibitors
US4876266A (en) 1987-12-31 1989-10-24 Smithkline Beckman Corporation 1-aralkyl-2-mercaptoimidazolines as DBH inhibitors
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4935449A (en) 1988-08-04 1990-06-19 Merrell Dow Pharmaceuticals Inc. N-2,3-butadienyl tri- and tetraaminoalkane derivatives
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5100912A (en) 1990-05-14 1992-03-31 Syntex (U.S.A.) Inc. Bis(benzylpyrrolidine) derivatives as dopamine agonists
US5108899A (en) 1989-10-31 1992-04-28 Exoxemis, Inc. Chemiluminescence assay of in vivo inflammation
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
DK0690863T3 (da) 1993-04-06 2003-06-30 Abbott Lab Tetracykliske forbindelser som dopamin-agonister
US5550139A (en) 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
ES2171911T3 (es) 1996-10-18 2002-09-16 Wisconsin Alumni Res Found Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
CA2366858A1 (en) * 1999-04-01 2000-10-12 Margaret Yuhua Chu-Moyer Sorbitol dehydrogenase inhibitors
IL146127A0 (en) 1999-04-30 2002-07-25 Slil Biomedical Corp Conformationally restricted polymine analogs as disease therapies
WO2000066175A2 (en) 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
IL153864A0 (en) 2000-08-02 2003-07-31 Slil Biomedical Corp Cyclic polyamine compounds and methods for the preparation thereof
WO2003012040A2 (en) 2001-07-27 2003-02-13 Baylor College Of Medecine Mutant nurr1 gene in parkinson's disease
WO2003070244A1 (en) * 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
AU2003247772A1 (en) * 2002-06-27 2004-01-19 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
US7899888B2 (en) * 2002-06-28 2011-03-01 Oracle America, Inc. Runtime versioning of information processing systems
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2542232A1 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
CN101466380A (zh) * 2006-02-16 2009-06-24 麦克莱恩医院 治疗帕金森病的方法和组合物
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
US20110045100A1 (en) 2008-03-05 2011-02-24 Georgetown University Antimalarial Quinolines and Methods of Use Thereof
US8628962B2 (en) 2008-11-18 2014-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Differentiation of stem cells into dopaminergic cells
US8658648B2 (en) * 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety

Also Published As

Publication number Publication date
EP2822936A2 (en) 2015-01-14
EP3971178A1 (en) 2022-03-23
EP2822936A4 (en) 2016-04-20
EP2822936B1 (en) 2021-09-08
US20220008418A1 (en) 2022-01-13
US11026943B2 (en) 2021-06-08
ES2899730T3 (es) 2022-03-14
PT2822936T (pt) 2021-12-02
US20170209441A1 (en) 2017-07-27
US20150023930A1 (en) 2015-01-22
US9567316B2 (en) 2017-02-14
WO2013134047A2 (en) 2013-09-12
WO2013134047A3 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
BR112015014678A2 (pt) lactamas fundidas com arila e heteroarila
EP3670496A3 (en) Acc2 inhibitors
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
Ferretti et al. Synthesis of symmetrically substituted 3, 3-dibenzyl-4-hydroxy-3, 4-dihydro-1H-quinolin-2-ones, as novel quinoline derivatives with antibacterial activity
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
JOP20200267A1 (ar) طريقة لتحضير (4s)-4-(4-سيانو-2-ميثوكسي فنيل)-5- إيثوكسي-8،2- ثنائي ميثيل-4،1- ثنائي هيدرو-1-6-نفثيريدين-3-كربوكس-اميد عن طريق فصل راسيمات بواسطة استرات حمض طرطريك دياستريومرية
MX394421B (es) Derivados de piridona policiclica sustituida y profarmaco de los mismos
MY165730A (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
BR112014010644A2 (pt) novos derivados de aril-quinolina
TN2009000342A1 (en) Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
MX338209B (es) Derivados de benzoxaborol para tratar infecciones bacterianas.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
IN2014CN03976A (enExample)
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
CR20150268A (es) Compuestos novedosos
PH12013501196B1 (en) Indeno- fused ring compounds having photochromic properties
BR112012029647A2 (pt) novos derivados de pirimidinas
MX2017003238A (es) Metodo para preparar 2'-o-fucosil-lactosa.
PH12016500480B1 (en) Antibacterial 2h-indazole derivatives
EA201692305A1 (ru) Антибактериальные хиназолин-4(3н)-оновые производные
MX356759B (es) Derivados de pirimidinona como agentes antimalaricos.
CR20160082A (es) Nuevo derivado de triazina